The FDA cleared the investigational new drug application for LTZ-301, a first-in-class myeloid engager immunotherapy, with a ...

Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...

Gwen Nichols, MD, discussed the potential implications of recent funding cuts, how they are affecting academic and community ...

A study found a 94% 6-month survival rate after tandem autologous stem cell transplant for high-risk neuroblastoma, but ...

Panelists discuss how the timing of therapeutic interventions in early-stage myelofibrosis must be carefully weighed against ...

Panelists discuss how treatment sequencing decisions in myelofibrosis should be guided by clinical evidence, patient response ...

Andrew Kuykendall, MD, discusses the background, methods, and design of a phase 2 study which evaluated fedratinib.

Kathryn Beckermann, MD, PhD, discusses the patient-reported outcomes for tivozanib plus nivolumab from the phase 3 TiNivo-2 ...

Bernstam, MD, discusses updated findings from the phase 1 TROPION-PanTumor01 study of datopotamab deruxtecan-dlnk in heavily ...

FDA approves vimseltinib for tenosynovial giant cell tumor and a triplet for R/R LBCL, plus the latest from ASCO GU 2025.

The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy ...

Panelists discuss how CARTITUDE-4 demonstrated superior progression-free survival and overall response rates with ...